Delcath Systems, Inc. (NASDAQ:DCTH) was the target of a significant growth in short interest in the month of July. As of July 31st, there was short interest totalling 42,417,695 shares, a growth of 31.3% from the July 14th total of 32,294,368 shares. Based on an average trading volume of 48,692,178 shares, the days-to-cover ratio is presently 0.9 days. Approximately 9.4% of the shares of the company are sold short.

An institutional investor recently raised its position in Delcath Systems stock. Renaissance Technologies LLC boosted its stake in Delcath Systems, Inc. (NASDAQ:DCTH) by 167.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 160,128 shares of the medical device company’s stock after buying an additional 100,214 shares during the period. Renaissance Technologies LLC owned 7.29% of Delcath Systems worth $147,000 at the end of the most recent quarter. Institutional investors own 0.54% of the company’s stock.

Shares of Delcath Systems (NASDAQ DCTH) opened at 0.0915 on Friday. The stock has a 50 day moving average price of $0.15 and a 200 day moving average price of $0.13. The firm’s market capitalization is $23.08 million. Delcath Systems has a 12-month low of $0.02 and a 12-month high of $4.31.

TRADEMARK VIOLATION NOTICE: “Delcath Systems, Inc. (NASDAQ:DCTH) Short Interest Update” was originally posted by Daily Political and is the sole property of of Daily Political. If you are accessing this article on another website, it was copied illegally and republished in violation of US and international copyright and trademark laws. The legal version of this article can be viewed at https://www.dailypolitical.com/2017/08/11/delcath-systems-inc-nasdaqdcth-short-interest-update.html.

Delcath Systems Company Profile

Delcath Systems, Inc is a late-stage clinical development company with early commercial activity in Europe focused on cancers of the liver. The Company is a specialty pharmaceutical and medical device company developing its product, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS).

Receive News & Ratings for Delcath Systems Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Delcath Systems Inc. and related companies with MarketBeat.com's FREE daily email newsletter.